Gene therapy offers to beat hepatitis B virus by muting its DNA
An experimental therapy called CRMA-1001 is a remarkable development because, instead of targeting the virus directly, it silences the viral DNA; this is promising because current treatments rarely…
Attributed summary
An experimental therapy called CRMA-1001 is a remarkable development because, instead of targeting the virus directly, it silences the viral DNA; this is promising because current treatments rarely eliminate the DNA, which allows the virus to rebound
Read the original report — The Hindu Health
Storywire publishes attributed summaries for discoverability. Full reporting remains with the original publisher — we do not republish restricted full text.
Related stories
